Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10008564 | 0.91 | SIRT2 (0.63) | SIRT2JAK2ZAP70SYKNPC1 | |
| SCHEMBL10009862 | 0.86 | JAK2 (0.60) | SIRT2JAK2ZAP70SYKNPC1 | |
| SCHEMBL10008337 | 0.86 | SIRT2 (0.60) | SIRT2JAK2ZAP70SYKNPC1 | |
| SCHEMBL10008147 | 0.86 | SIRT2 (0.55) | SIRT2JAK2ZAP70SYKNPC1 | |
| SCHEMBL10007958 | 0.85 | SIRT2 (0.57) | SIRT2JAK2ZAP70SYKNPC1 | |
| SCHEMBL10299104 | 0.85 | MAPT (0.63) | SIRT2JAK2ZAP70SYKNPC1 | |
| SCHEMBL10009184 | 0.85 | NPC1 (0.56) | SIRT2JAK2ZAP70SYKNPC1 | |
| SCHEMBL10009445 | 0.84 | ABL1 (0.57) | SIRT2NPC1RAB9ALMNATP53 | |
| SCHEMBL10008888 | 0.83 | SIRT2 (0.58) | SIRT2JAK2ZAP70SYKNPC1 | |
| SCHEMBL10008023 | 0.83 | KMT2A (0.63) | NPC1RAB9ALMNAMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883793-B2 | Tubulin inhibitors and methods of using the same | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-11-11 | — | — | US | claimed |
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | US | claimed |
| WO-2012092471-A2 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | WO | claimed |
| US-8883793-B2 | Tubulin inhibitors and methods of using the same | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-11-11 | — | — | US | disclosed |
| US-8883793-B2 | Tubulin inhibitors and methods of using the same | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-11-11 | — | — | US | disclosed |
| US-8883793-B2 | Tubulin inhibitors and methods of using the same | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-11-11 | — | — | US | disclosed |
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | US | disclosed |
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | US | disclosed |
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172374-A1 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME | TUBB1, TUBA1C, TUBB | SIRT2 3179/4885JAK2 2436/4885ZAP70 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.